Literature DB >> 12666192

Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European Society of Gene Therapy (ESGT).

Bernd Gansbacher1.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12666192     DOI： 10.1002/jgm.390

Source DB:  PubMed          Journal:  J Gene Med        ISSN： 1099-498X            Impact factor:   4.565


× No keyword cloud information.
  4 in total

Review 1.  Viral vectors: from virology to transgene expression.

Authors:  D Bouard; D Alazard-Dany; F-L Cosset
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

Review 2.  Clinical application of vascular regenerative therapy for peripheral artery disease.

Authors:  Hiroshi Suzuki; Yoshitaka Iso
Journal:  Biomed Res Int       Date:  2013-11-24       Impact factor: 3.411

3.  Gene therapies development: slow progress and promising prospect.

Authors:  Eve Hanna; Cécile Rémuzat; Pascal Auquier; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2017-01-03

4.  Long-term gene therapy with Del1 fragment using nonviral vectors in mice with explanted tumors.

Authors:  Hisataka Kitano; Atsushi Mamiya; Tomomi Ishikawa; Kayo Egoshi; Shinichiro Kokubun; Chiaki Hidai
Journal:  Onco Targets Ther       Date:  2016-01-25       Impact factor: 4.147
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.